Kevin Leach Announced as AxoGen, Inc New VP of Marketing
AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Kevin Leach as Vice President of Marketing effective March 14, 2016. Mr. Leach will report directly to Karen Zaderej, President and Chief Executive Officer and will be responsible for AxoGen’s global marketing strategies and functions.
“The addition of Kevin to our senior leadership team enhances our efforts to shift surgeon treatment algorithms to AxoGen’s portfolio of nerve repair products, including Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector,” commented Karen Zaderej, President and Chief Executive Officer. “I am confident his extensive medical device industry experience, both domestically and internationally, will drive AxoGen’s marketing and surgeon education efforts to new levels of success and will play a critical role in the execution of our growth strategy.”
Prior to joining AxoGen, Mr. Leach was the Vice President, Global Knee Marketing of Stryker Corporation, a medical technology company offering innovative products and services in Orthopaedics, Medical and Surgical, Neurotechnology and Spine. Prior to Stryker, he served in marketing roles with increasing responsibility and lastly as Vice President, Americas, Wound Therapeutics & Critical Care at ConvaTec Inc., a private-equity held global medical products and technologies company, with leading market positions in wound therapeutics, ostomy care, continence and critical care, and infusion devices. Prior to moving to the United States Mr. Leach was a global marketing leader for ConvaTec (a Bristol-Myers Squibb company) where he led the launch of new products globally. He also served with Zimmer UK, a medical device company where he headed a newly established division for the Orthopaedic business unit focusing on market development and commercialization of an injectable Hyaluronic Acid for the relief of joint pain. Mr. Leach received his Diploma in Podiatric Medicine from Queen Margaret University in Edinburgh.
“AxoGen has just completed a year of tremendous growth, and is poised to continue its market momentum for the foreseeable future,” said Mr. Leach. “I look forward to working with Karen and the rest of our team to build on our success and accelerate the adoption of AxoGen’s nerve repair products.”
About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.
Read more: http://www.virtual-strategy.com/2016/03/14/kevin-leach-appointed-vice-president-marketing-axogen-inc#ixzz43AjlYjCV